NCT03597386 is a clinical trial in Prostate Disease, sponsored by University of Rochester.

Who is sponsoring NCT03597386?

NCT03597386 is sponsored by University of Rochester.

What condition does NCT03597386 study?

NCT03597386 studies Prostate Disease.

Is NCT03597386 still recruiting?

NCT03597386 is currently withdrawn. Last updated 1 March 2019.

Last reviewed 2019-03-01 · How we verify

NCT03597386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ConfirmMDx Assay in Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy

Withdrawn Last updated 1 March 2019

What this trial tests

trial in Prostate Disease. Withdrawn.

Timeline

23 January 2019

Primary endpoint
24 January 2019

24 January 2019

Quick facts

Lead sponsor	University of Rochester
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	23 January 2019
Primary completion	24 January 2019
Estimated completion	24 January 2019
Sites	1 location across United States

Conditions studied

Prostate Disease — all drugs for Prostate Disease →

Sponsor

University of Rochester

Who can join

Adults 18 to 80, male only, with Prostate Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see if the ConfirmMDx assay is useful in finding prostate cancer in patients who are at increased risk for prostate cancer based on elevated PSA and prostate lesion identified on mpMRI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Disease

Currently open trials in the same condition.

NCT07130708 — Exploring the Potential of Robotic Telesurgery in Remote Settings · NA · recruiting
NCT06944743 — TURP Inpatient With Underactive Bladder With BOO · NA · recruiting
NCT06636747 — High Resolution Diffusion Weighted Imaging in Prostate · recruiting
NCT05682742 — Clinical Investigation of the da Vinci Surgical System · NA · active not recruiting
NCT04288427 — 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy · NA · recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03597386 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 1 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03597386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing